Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | SCN4A | P35499 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12355859 | 0.83 | KDM4E (0.66) | KDM4EBACE1EPHX2SCN4APKM | |
| SCHEMBL12355858 | 0.83 | KDM4E (0.66) | KDM4EBACE1EPHX2SCN4APKM | |
| SCHEMBL11809163 | 0.81 | KDM4E (0.63) | KDM4EBACE1EPHX2SCN4APKM | |
| SCHEMBL13641613 | 0.81 | KDM4E (0.63) | KDM4EBACE1EPHX2SCN4ADGAT1 | |
| SCHEMBL30829253 | 0.79 | KDM4E (0.53) | KDM4EBACE1EPHX2SCN4APKM | |
| SCHEMBL437476 | 0.79 | KDM4E (0.61) | KDM4EBACE1EPHX2SCN4APKM | |
| SCHEMBL5160237 | 0.78 | KDM4E (0.59) | KDM4EBACE1EPHX2SCN4APKM | |
| SCHEMBL12340102 | 0.78 | KDM4E (0.59) | KDM4EBACE1EPHX2SCN4ADGAT1 | |
| SCHEMBL29187262 | 0.77 | KDM4E (0.50) | KDM4EBACE1EPHX2SCN4APKM | |
| SCHEMBL10849169 | 0.77 | KDM4E (0.59) | KDM4EBACE1EPHX2SCN4APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7081346-B2 | Method of screening binding of a compound to a receptor | MARQUETTE UNIVERSITY (US) | 2006-07-25 | — | — | US | disclosed |
| US-20030215959-A1 | Method of screening binding of a compound to a receptor | MARQUETTE UNIVERSITY | 2003-11-20 | — | — | US | disclosed |
| EP-0260467-B1 | Quinoxaline compounds and their preparation and use | NOVO NORDISK AS (DK) | 1993-12-29 | — | — | EP | disclosed |
| US-4812458-A | 6,7-disubstituted-2,3-dihydroxyquinoxaline compounds, pharmaceutical compositions thereof, and their use as neuroleptics | A/S FERROSAN (DK) | 1989-03-14 | — | — | US | disclosed |
| EP-0260467-A2 | Quinoxaline compounds and their preparation and use | NOVO NORDISK A/S (DK) | 1988-03-23 | — | — | EP | disclosed |
| US-4200748-A | ANXIOLYTIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1980-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030215959-A1 | Method of screening binding of a compound to a receptor | FSHR, GRB7, GPR174 | KDM4E 4645/4885BACE1 4521/4885EPHX2 3411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.